Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Research Funding » Golden Helix Gets $1.8M to Improve Detection Algorithms for Complex Variants in NGS Data

Golden Helix Gets $1.8M to Improve Detection Algorithms for Complex Variants in NGS Data

Sep 17, 2018
|
Uduak Grace Thomas
Premium

NEW YORK (GenomeWeb) – Armed with a $1.8 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health, Bozeman, Montana-based bioinformatics company Golden Helix is developing and refining proprietary algorithms for detecting copy number variants and other structural variants from next-generation sequencing data in clinical contexts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Another Paper Gone

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational Biologist James Taylor Dies

Computational biologist James Taylor has died, according to Johns Hopkins University.

Ever Infected

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

PLOS Papers on Hepatocellular Carcinoma Immune Cells, Regulatory Prostate Cancer Risk SNPs, More

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Informatics

  1. Gilead Sciences, Second Genome Partner for Microbiome-Based IBD Biomarker, Drug Discovery

  2. Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.